https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Tue, 09 Jun 2026 00:00:00 GMT https://oncbrain.oncologytoolkit.com/2026-06-09/#firestorm-meningioma https://oncbrain.oncologytoolkit.com/2026-06-09/#firestorm-meningioma Tue, 09 Jun 2026 00:00:00 GMT cns [Caveats dominate] 5-yr PFS 65.8% vs 38.8%, HR 0.40 favoring dose-escalated RT in high-risk meningioma; retrospective IPD meta-analysis. Eligible: High-risk meningioma (WHO grade 2 or recurrent), post-resection (mostly subtotal https://oncbrain.oncologytoolkit.com/2026-05-19/#sf-sabr-nsclc-oligomets-pooled https://oncbrain.oncologytoolkit.com/2026-05-19/#sf-sabr-nsclc-oligomets-pooled Tue, 19 May 2026 00:00:00 GMT thoracic [Early signal] 2yr LC 90-93%, G3+ AEs 2.9% across 1687 pts treated with SF-SABR at 3 institutions. Eligible: Inoperable primary NSCLC or pulmonary oligomets, multi-institution pooled cohort https://oncbrain.oncologytoolkit.com/2026-05-18/#hcc-ebrt-ipd-multinational https://oncbrain.oncologytoolkit.com/2026-05-18/#hcc-ebrt-ipd-multinational Mon, 18 May 2026 00:00:00 GMT hepatobiliary [Confirmatory] BCLC-A mOS 4.6yr, BCLC-0 6.8yr in 4,913-pt IPD cohort; OS comparable to resection and ablation. Eligible: HCC BCLC-0 or BCLC-A, treatment-naïve or previously treated